Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
about
Rituximab, ofatumumab and other monoclonal anti-CD20 antibodies for chronic lymphocytic leukaemiaThe outliers become a stampede as immunometabolism reaches a tipping pointInfection risk in patients on multiple sclerosis therapeutics.Severe and fatal adverse events risk associated with rituximab addition to B-cell non-Hodgkin's lymphoma (B-NHL) chemotherapy: a meta-analysis.The risk of infections in hematologic patients treated with rituximab is not influenced by cumulative rituximab dosage - a single center experience.Infections in patients taking Rituximab for hematologic malignancies: two-year cohort study.High expression levels of BLyS/BAFF by blood dendritic cells and granulocytes are associated with B-cell dysregulation in SIV-infected rhesus macaques.Clinical Significance of Non-neutropenic Fever in the Management of Diffuse Large B-Cell Lymphoma Patients Treated with Rituximab-CHOP: Comparison with Febrile Neutropenia and Risk Factor AnalysisPhase 2 study of rituximab-ABVD in classical Hodgkin lymphoma.Rituximab in idiopathic membranous nephropathy.Poorly differentiated synovial sarcoma is associated with high expression of enhancer of zeste homologue 2 (EZH2)Transient removal of CD46 is safe and increases B-cell depletion by rituximab in CD46 transgenic mice and macaques.Fludarabine-based versus CHOP-like regimens with or without rituximab in patients with previously untreated indolent lymphoma: a retrospective analysis of safety and efficacy.Cancer immunotherapy takes a multi-faceted approach to kick the immune system into gear.Rituximab for refractory granulomatous eye disease.Rituximab therapy in nephrotic syndrome: implications for patients' management.Primary prophylaxis of bacterial infections and Pneumocystis jirovecii pneumonia in patients with hematological malignancies and solid tumors : guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society of Hematology and OncolDisseminated toxoplasmosis in non-allografted patients with hematologic malignancies: report of two cases and literature review.Infectious complications of immune modulatory agents.Multiple sclerosis treatment and infectious issues: update 2013.Hypogammaglobulinaemia after rituximab treatment-incidence and outcomes.Necrotising fasciitis after bortezomib and dexamethasone-containing regimen in an elderly patient of Waldenström macroglobulinaemia.Clinical management of pulmonary sarcoidosis.Treatment of membranous nephropathy: time for a paradigm shift.Rituximab therapy for primary glomerulonephritis: Report on two casesCharacterization of the B cell response to Leishmania infection after anti-CD20 B cell depletion.[Infection risks in multiple sclerosis therapy by infusion of disease modifying drugs].B cell depletion curtails CD4+ T cell memory and reduces protection against disseminating virus infection.Immunosuppressive therapy for eye diseases: Effectiveness, safety, side effects and their prevention.A Case of Rituximab-Induced Necrotizing Fasciitis and a Review of the Literature.Serious infection risk after 1 year between patients with rheumatoid arthritis treated with rituximab or with a second TNFi after initial TNFi failure: results from The British Society for Rheumatology Biologics Register for Rheumatoid Arthritis.Long-term outcomes of primary ocular adnexal lymphoma treatment with intraorbital rituximab injections.Phase II study of first-line (131)I-rituximab radioimmunotherapy in follicular non-Hodgkin lymphoma and prognostic (18)F-fluorodeoxyglucose positron emission tomography.
P2860
Q24203027-B490BA1B-9985-4552-83CC-8DEA9261F630Q27005951-C7267690-27DA-4243-91B1-8A2427A5DC46Q30908652-681C85EB-6EE7-4086-A792-016AF7813524Q33421964-7AE0808C-6FD6-420F-A590-4659C09E6260Q34486116-2B8412ED-E711-4D5C-80B2-A07A4F708E10Q34815753-DECE9B57-F72D-4618-9E69-BEBBD31DAE4FQ35672894-5AFAC609-FB86-4BE0-8543-6715085A1702Q35862322-CFD6F5E9-59B0-4269-A146-6DF3BF06FB18Q35986609-A18BF6E5-C75C-476B-BB6D-228B5E25A61AQ36109197-59FA92A2-2990-4EEE-B9DA-8D84E231CB68Q36388149-A4565D7D-260D-46AE-A6B7-36B18F5F8E9DQ36673736-59761B45-9196-44B2-A916-F008629297FDQ37231130-6192D6D1-8F23-41FC-B008-ED3DE3FAD700Q37969745-912D1038-4218-471C-9171-AEE5AF4301FAQ38051300-F23BD6AB-1C90-4FB6-89D3-455B48FB9D4BQ38075787-F05F82DC-1A46-49BA-BC44-94769AEA2E25Q38081793-6ABC63FF-0D08-4CD1-903F-9ED8DCD2EEBDQ38099782-06868CA9-4C44-468A-BC6F-DA690A195E4CQ38144976-366F85EC-2FB1-4828-BB27-43ACB40B7299Q38153471-9A56EB92-60EC-4D3C-BFA2-D9056BEE07A2Q38207970-E38F86C8-09B3-420E-9748-E54B6B9F719EQ38613720-A4B547F3-D54D-42FD-839C-433DD9E32947Q38766783-C9BBC06C-F1A5-47BE-9D7B-98B2475DF664Q39410091-4B63AD05-B8D2-43D2-AC7E-41840F894E5AQ41036642-9DA4AF29-183A-4E17-A5AD-A3C45AE90379Q41059758-12622130-18B8-4F7D-AE69-6A56F42B5D5BQ41102105-87435A46-AF60-4C43-946A-D68F5AA0C781Q41957699-088C5D73-F457-4E7F-9FB1-4F6ADA9ADA4FQ42359937-1E2B7B48-A9C1-4A20-9B42-C72760FF46A2Q42706755-16A80022-7DBD-44B2-AB75-06A102C35F9DQ47883430-B74B0F74-FC0F-41DD-AFF8-DAE8941C3128Q51034531-F7D60579-2F3B-4747-A59E-23C46F742E60Q53058794-066447EA-7AA7-43D0-87CB-5D2D514699F9
P2860
Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
description
2011 nî lūn-bûn
@nan
2011 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
Risk of infection in patients ...... matic review and meta-analysis
@ast
Risk of infection in patients ...... matic review and meta-analysis
@en
type
label
Risk of infection in patients ...... matic review and meta-analysis
@ast
Risk of infection in patients ...... matic review and meta-analysis
@en
prefLabel
Risk of infection in patients ...... matic review and meta-analysis
@ast
Risk of infection in patients ...... matic review and meta-analysis
@en
P2093
P2860
P31
P921
P356
P1433
P1476
Risk of infection in patients ...... matic review and meta-analysis
@en
P2093
Aoife C Molloy
Archibald G Prentice
Christopher C Kibbler
Paul E Fine
P2860
P2888
P356
10.1186/1741-7015-9-36
P407
P5008
P577
2011-04-12T00:00:00Z
P5875
P6179
1028951594